微小染色体维持蛋白7与geminin的表达：在接受放疗和西妥昔单抗治疗的喉鳞状细胞癌患者中的预后价值。

Minichromosome maintenance protein 7 and geminin expression: Prognostic value in laryngeal squamous cell carcinoma in patients treated with radiotherapy and cetuximab.

作者信息

Almadori Giovanni, Lauriola Libero, Coli Antonella, Bussu Francesco, Gallus Roberto, Scannone Domenico, Valentini Vincenzo, Paludetti Gaetano, Carey Thomas E, Ranelletti Franco O

机构信息

Institute of Otolaryngology, Head and Neck Surgery, Catholic University of Sacred Heart, Rome, Italy.

Institute of Anatomic Pathology, Catholic University of Sacred Heart, Rome, Italy.

出版信息

Head Neck. 2017 Apr;39(4):684-693. doi: 10.1002/hed.24670. Epub 2016 Dec 29.

DOI:10.1002/hed.24670

PMID:28032719

Abstract

BACKGROUND

Minichromosome maintenance protein 7 (MCM7) is a downstream of human epidermal growth receptor (HER1) signaling. We examined MCM7, geminin, and HER1 expression in patients with laryngeal squamous cell carcinoma (SCC) treated with radiotherapy and cetuximab.

METHODS

MCM7, geminin, and HER1 were evaluated by immunohistochemistry on 61 patients with laryngeal SCC. The follow-up (median, 32.1 months; range, 2-139 months) went from the beginning of therapy to tumor progression-free survival (PFS) and death (overall survival [OS]).

RESULTS

MCM7, but not geminin, was associated only with HER1 expression, whereas no association was found with other clinicopathological characteristics. Patients with MCM7 high - geminin high and MCM7 high - geminin low tumor status had a risk of progression 3.1 times and 17.7 times greater, respectively, than patients with MCM7 low - geminin high tumor status. Tumor site, MCM7, and geminin were independent determinants of PFS, whereas MCM7 was an independent prognostic marker of OS.

CONCLUSION

摘要

背景

微小染色体维持蛋白7（MCM7）是人类表皮生长受体（HER1）信号通路的下游分子。我们检测了接受放疗和西妥昔单抗治疗的喉鳞状细胞癌（SCC）患者中MCM7、geminin和HER1的表达情况。

方法

对61例喉鳞状细胞癌患者进行免疫组化检测MCM7、geminin和HER1。随访（中位时间为32.1个月；范围为2 - 139个月）从治疗开始至无肿瘤进展生存期（PFS）和死亡（总生存期[OS]）。

结果

MCM7仅与HER1表达相关，而与geminin无关，且未发现与其他临床病理特征相关。MCM7高 - geminin高和MCM7高 - geminin低肿瘤状态的患者进展风险分别比MCM7低 - geminin高肿瘤状态的患者高3.1倍和17.7倍。肿瘤部位、MCM7和geminin是PFS的独立决定因素，而MCM7是OS的独立预后标志物。